FCS Real-World Evidence Abstract Highlights Progress and Gaps in Biomarker Testing for Lung Cancer

Fort Myers, Fla., June 4, 2026 –Rami Owera, MD, medical oncologist and hematologist with Woodlands Specialty Physicians, a division of Florida Cancer Specialists & Research Institute is co-author of an abstract detailing findings from the MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Cancer Network) Consortium Protocol 2, a prospective real-world study examining patterns in biomarker testing, treatment decision-making, and the barriers and workflows that shape care for patients with lung cancer in community settings.

The study, published in the Journal of Clinical Oncology, provides early insights into how patients with newly diagnosed non-small cell lung cancer (NSCLC) are tested and treated in community oncology settings.

“We’re seeing meaningful progress in biomarker testing for lung cancer, particularly in the use of more comprehensive genomic profiling,” said Dr. Owera. “At the same time, gaps remain in ensuring all patients receive complete results before starting treatment—an essential step in delivering truly personalized care—underscoring opportunities to strengthen workflows, access and lung cancer care overall.”

FCS President & Managing Physician Lucio N. Gordan, MD said, “These findings confirm the critical importance of FCS’ ongoing expansion of genomic testing capabilities to ensure patients consistently receive the right test at the right time and fully realize the benefits of precision oncology.”

The study, which aims to track up to 12,000 patients, is part of the broader MYLUNG Consortium initiative engaging leading oncology practices, researchers and industry partners to generate real-world evidence and identify strategies to enhance personalized care delivery and improve outcomes for patients with lung cancer. Dr. Owera noted that MYLUNG Protocol 3 will continue to explore interventions that have demonstrated promise in enhancing effectiveness in biomarker testing.

Dr. Owera is actively involved in clinical research as a principal investigator and sub-investigator in collaboration with the Sarah Cannon Research Institute. His research has included numerous clinical trials across a wide range of malignancies, including breast, lung, gastrointestinal and hematologic cancers.